Icatibant
Bradykinin B2 antagonist for hereditary angioedema (HAE). Selective peptide inhibitor of bradykinin-mediated vascular permeability, providing rapid symptom relief in acute HAE attacks.
Icatibant is a selective bradykinin B2 receptor antagonist and a synthetic decapeptide used for the treatment of acute attacks of hereditary angioedema (HAE). As an orphan drug, icatibant competitively blocks bradykinin binding to B2 receptors, inhibiting bradykinin-mediated vascular permeability increase and edema formation, thereby rapidly relieving acute symptoms in HAE patients.
| Parameter | Specification |
| CAS | 30308-48-4 |
| Molecular Formula | C₅₉H₈₉N₁₉O₁₃S |
| Molecular Weight | 1304.52 g/mol |
| Category | Cardiovascular |
| Purity | ≥99% |
| Status | GMP-compliant, FDA-ready |
| Applications | Hereditary angioedema, bradykinin-mediated edema, acute HAE attacks |
| CAS | 30308-48-4 |
|---|---|
| Applications | Bradykinin Antagonist, Hereditary Angioedema, Inflammation Control |
Related products
-
Liraglutide
CAS: 204656-20-2Applications: cardiovascular risk reduction, GLP-1, obesity management -
Retatrutide
CAS: 2381089-83-2Applications: Refractory diabetes, Severe obesity, Triple agonist, weight management -
Leuprorelin Acetate
CAS: 74381-53-6Applications: Breast Cancer, Endometriosis, Precocious Puberty, Prostate Cancer -
Pramlintide
CAS: 196078-30-5